Imunon Inc (IMNN)vsNovartis AG ADR (NVS)
IMNN
Imunon Inc
$1.47
+1.38%
HEALTHCARE · Cap: $8.75M
NVS
Novartis AG ADR
$137.16
-0.23%
HEALTHCARE · Cap: $260.70B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 45354298% more annual revenue ($56.69B vs $125,000). NVS leads profitability with a 22.5% profit margin vs 0.0%. NVS appears more attractively valued with a PEG of 3.22. NVS earns a higher WallStSmart Score of 51/100 (C-).
IMNN
Avoid23
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IMNN.
Margin of Safety
-47.0%
Fair Value
$93.29
Current Price
$137.16
$43.87 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : IMNN
IMNN has a balanced fundamental profile.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bear Case : IMNN
The primary concerns for IMNN are Revenue Growth, EPS Growth, Market Cap. Debt-to-equity of 1.87 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Key Dynamics to Monitor
IMNN carries more volatility with a beta of 1.97 — expect wider price swings.
NVS is growing revenue faster at 0.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 23/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Imunon Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Imunon Inc. is a clinical-stage biotechnology company at the forefront of developing innovative immune-mediated therapies targeting cancer and infectious diseases. Leveraging its proprietary INFECT platform, Imunon aims to enhance immune response mechanisms, facilitating effective tumor eradication. With a diversified pipeline of therapeutics across multiple clinical stages and strategic collaborations that bolster its operational expertise, Imunon is strategically positioned to revolutionize immunotherapy, offering the potential to significantly enhance treatment outcomes for patients while shaping the future of the biopharmaceutical landscape.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?